Dusel Succeeds in World’s First Production of Artificial Platelets Using a 50-Liter Bioreactor

Dusel, a company specializing in the development of artificial platelets, announced that it has succeeded in producing artificial platelets using a 50-liter bioreactor for the first time in the world.

At the end of last year, Dusel established a production process for artificial platelets using a 50-liter bioreactor at its corporate research institute, also a world first. On January 30, the company stated that this achievement enabled the mass production of artificial platelets. This accomplishment is significant as it demonstrates the potential for scaling up beyond the previous small-scale bioreactor stage, paving the way for clinical application and commercialization.

Production of artificial platelets in a 50-liter bioreactor. Dusel

Additionally, Dusel plans to introduce two 50-liter bioreactors from the global bio equipment company Sartorius to its Anyang plant within the first half of this year, and to commence full-scale mass production using the manufacturing technology established at its research institute.

Establishing a mass production process in the field of artificial platelets is considered one of the most significant challenges to commercialization. In fact, Dusel’s competitor, Japan’s Megakaryon, developed the world’s first iPSC-based artificial platelets and demonstrated safety in a Phase 1 clinical trial by producing clinical samples using four 10-liter bioreactors. However, the company has continued to develop technology for process scale-up and recently announced the development of a process using a 45-liter bioreactor. From its inception, Dusel has focused on overcoming these limitations by making the establishment of a mass production process its core strategy and concentrating on technology development.

A Dusel representative stated, “The success of producing artificial platelets in a 50-liter bioreactor is a key milestone for the clinical application and commercialization of artificial platelet technology. By securing a mass production process system early, we can further accelerate the research and development of therapeutics and biomaterials utilizing artificial platelets.”

Industry experts believe that the success of artificial platelet production in a 50-liter bioreactor will significantly accelerate the commercialization of core technologies related to artificial platelet production. As artificial platelets are considered a high-growth potential sector in the global biopharmaceutical industry, Dusel’s enhanced production capabilities are expected to have a positive impact on the domestic regenerative medicine industry as well.

This content was produced with the assistance of AI translation services.